{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:17:07Z","timestamp":1789510627235,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euros.2025.11.005","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:50:41Z","timestamp":1764852641000},"page":"54-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-669X","authenticated-orcid":false,"given":"Keiichiro","family":"Miyajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman S.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed R.","family":"Alfarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.11.005_b0005","doi-asserted-by":"crossref","unstructured":"Matsukawa A, Cormio A, Miszczyk M, et al. Impact of immune checkpoint inhibitors as neoadjuvant therapy for muscle-invasive bladder cancer: a systematic review, meta-analysis, and network meta-analysis. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2025.02.009.","DOI":"10.1016\/j.euo.2025.02.009"},{"key":"10.1016\/j.euros.2025.11.005_b0010","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.euf.2024.11.003","article-title":"Trimodality therapy versus radical cystectomy for muscle-invasive bladder cancer: a systematic review and meta-analysis of matched cohort studies","volume":"11","author":"Matsukawa","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2025.11.005_b0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2013.09.050","article-title":"Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.11.005_b0020","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.11.005_b0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043266","article-title":"Short-term morbidity and mortality following radical cystectomy: a systematic review","volume":"11","author":"Maibom","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.euros.2025.11.005_b0030","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrurol.2014.151","article-title":"Sexual dysfunction after cystectomy and urinary diversion","volume":"11","author":"Modh","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euros.2025.11.005_b0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2025.11.005_b0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2025.02.051","article-title":"Survival outcomes and temporal trends of non-surgical management vs radical cystectomy in non-organ-confined urothelial bladder cancer","volume":"200","author":"Longoni","year":"2025","journal-title":"Urology"},{"key":"10.1016\/j.euros.2025.11.005_b0045","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7306198","article-title":"Comparing long-term survival outcomes for muscle-invasive bladder cancer patients who underwent with radical cystectomy and bladder-sparing trimodality therapy: a multicentre cohort analysis","volume":"2022","author":"Qiu","year":"2022","journal-title":"J Oncol"},{"key":"10.1016\/j.euros.2025.11.005_b0050","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.11.005_b0055","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2025.11.005_b0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12894-020-00733-z","article-title":"Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients","volume":"20","author":"Hamid","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.euros.2025.11.005_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.euros.2025.11.005_b0070","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2025.11.005_b0075","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.euros.2025.11.005_b0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.euros.2025.11.005_b0085","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euros.2025.11.005_b0090","article-title":"Introduction to the GRADE tool for rating certainty in evidence and recommendations","volume":"25","author":"Prasad","year":"2024","journal-title":"Clin Epidemiol Global Health"},{"key":"10.1016\/j.euros.2025.11.005_b0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0041-1723076","article-title":"Bladder preservation with neoadjuvant chemotherapy followed by concurrent chemoradiation for the treatment of muscle-invasive carcinoma of the bladder: a single-center experience","volume":"9","author":"Agrawal","year":"2020","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.euros.2025.11.005_b0100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ajur.2021.06.006","article-title":"A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer","volume":"9","author":"Dracham","year":"2022","journal-title":"Asian J Urol"},{"key":"10.1016\/j.euros.2025.11.005_b0105","first-page":"1","article-title":"Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer","volume":"27","author":"Elsayed","year":"2023","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.euros.2025.11.005_b0110","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5489\/cuaj.6459","article-title":"Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer","volume":"14","author":"Ajib","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euros.2025.11.005_b0115","doi-asserted-by":"crossref","first-page":"893","DOI":"10.4143\/crt.2024.015","article-title":"Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder: post hoc analysis of two prospective studies","volume":"56","author":"Cho","year":"2024","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.euros.2025.11.005_b0120","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.urology.2004.04.088","article-title":"Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy","volume":"64","author":"George","year":"2004","journal-title":"Urology"},{"issue":"4_suppl","key":"10.1016\/j.euros.2025.11.005_b0125","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2024.42.4_suppl.577","article-title":"Outcomes with neoadjuvant chemotherapy in bladder-preserving treatment for MIBC","volume":"42","author":"Glover","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.11.005_b0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clgc.2018.09.021","article-title":"Neoadjuvant chemotherapy before bladder-sparing chemoradiotherapy in patients with nonmetastatic muscle-invasive bladder cancer","volume":"17","author":"Jiang","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2025.11.005_b0135","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.euo.2024.01.014","article-title":"Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: an inverse probability treatment weighted analysis","volume":"7","author":"Kool","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2025.11.005_b0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5430\/jst.v5n2p59","article-title":"Continuous chemoradiation following complete response to neo-adjuvant chemotherapy provides improved outcomes in muscle invasive urothelial carcinoma","volume":"5","author":"L\u00f3pez-Araujo","year":"2015","journal-title":"J Solid Tumors"},{"key":"10.1016\/j.euros.2025.11.005_b0145","first-page":"122","article-title":"Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer","volume":"14","author":"Nguyen","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euros.2025.11.005_b0150","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clgc.2021.03.007","article-title":"Trimodality therapy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"19","author":"Royce","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2025.11.005_b0155","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2016.11.040","article-title":"Tolerability of concurrent chemoradiation therapy with gemcitabine (GemX), with and without prior neoadjuvant chemotherapy, in muscle invasive bladder cancer","volume":"97","author":"Thompson","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euros.2025.11.005_b0160","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.11.005_b0165","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.11.005_b0170","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.11.005_b0175","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.euf.2023.04.009","article-title":"For which patients should bladder preservation be considered after a complete response to neoadjuvant chemotherapy","volume":"9","author":"Laukhtina","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"4_suppl","key":"10.1016\/j.euros.2025.11.005_b0180","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS720","article-title":"Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC)","volume":"42","author":"Gupta","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euros.2025.11.005_b0185","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1200\/JCO.2021.39.6_suppl.428","article-title":"INTACT (S\/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: safety update on first 73 patients","volume":"39","author":"Singh","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.11.005_b0190","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.11.005_b0195","doi-asserted-by":"crossref","unstructured":"Lee J, Chen F, Lopez-Beltran A, et al. Urinary tumor DNA-based liquid biopsy in bladder cancer management: a systematic review. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2025.06.009.","DOI":"10.1016\/j.euf.2025.06.009"},{"key":"10.1016\/j.euros.2025.11.005_b0200","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2025.07.016","article-title":"The role of liquid biopsy in the management of patients with genitourinary malignancies","volume":"88","author":"Maughan","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.11.005_b0205","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.euros.2025.11.005_b0210","doi-asserted-by":"crossref","first-page":"S1133","DOI":"10.1016\/j.annonc.2024.08.2045","article-title":"1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial","volume":"35","author":"Bjerggaard Jensen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2025.11.005_b0215","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euros.2025.11.005_b0220","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS585","article-title":"Phase 3 KEYNOTE-905\/EV-303: perioperative pembrolizumab (pembro) or pembro\u00a0+\u00a0enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC)","volume":"41","author":"Necchi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euros.2025.11.005_b0225","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS588","article-title":"Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): phase 3 KEYNOTE-B15\/EV-304","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325024693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325024693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:39:09Z","timestamp":1773873549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168325024693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":45,"alternative-id":["S2666168325024693"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.11.005","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}